Application of chitosan oligosaccharide and vaccine containing chitosan oligosaccharide

A chitosan oligosaccharide and vaccine technology, applied in the field of immunology, can solve the problems of strong toxic and side effects and high cost, and achieve the effects of no toxic and side effects, low cost and simple preparation process

Inactive Publication Date: 2015-05-20
INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
View PDF0 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] In order to solve the problems of high cost and strong side effects of existing vaccine adjuvants, the present invention provides a safe, effective, simple and low-cost chitosan adjuvant and a vaccine agent containing chitosan adjuvant

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of chitosan oligosaccharide and vaccine containing chitosan oligosaccharide
  • Application of chitosan oligosaccharide and vaccine containing chitosan oligosaccharide
  • Application of chitosan oligosaccharide and vaccine containing chitosan oligosaccharide

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0018] The hepatitis A vaccine containing oligochitosan adjuvant provided in this example is: according to the amount of 2.5 mg chitosan oligosaccharide added to each single vaccine dose, chitosan oligosaccharide dissolved in 50 μL sterile water is added to the hepatitis A (HAV) antigen, and then Add physiological saline to 200 μL, and mix uniformly according to the routine to obtain the hepatitis A vaccine agent containing chitosan oligosaccharide.

[0019] Among them, chitosan oligosaccharide is a commercially available product, which is formed by the polymerization of 2 to 10 glucosamine, and has a molecular weight of less than 3000. It is purchased from Hubei Weideli Chemical Technology Co., Ltd.; 18EU HAV antigen solution was provided by the Institute of Medical Biology, Chinese Academy of Medical Sciences, Peking Union Medical College.

[0020] The immunization experiment and effect of the hepatitis A vaccine that embodiment 1 gained contains chitosan oligosaccharide adj...

Embodiment 2

[0036] The hepatitis A vaccine containing oligochitosan adjuvant provided in this example is: add 5 mg of chitosan oligosaccharide to each single vaccine dose, add chitosan oligosaccharide dissolved in 100 μL sterile water to the hepatitis A (HAV) antigen, and then add Physiological saline to 200 μL, and mix uniformly according to routine to obtain a vaccine agent containing chitosan oligosaccharide. Wherein, chitosan oligosaccharide, HAV antigen are with embodiment 1;

[0037] The immunization experiment of the hepatitis A vaccine containing the chitosan oligosaccharide adjuvant obtained in this example is the same as in Example 1, and the results are shown in Table 2.

[0038] Table 2 is after using the adjuvant provided by Example 2, within 16 weeks, the serum anti-HAV IgG antibody levels of mice in each experimental group:

[0039] Table 2

[0040]

[0041] From the data analysis, it can be seen that from the 4th week after immunization, all experimental groups except...

Embodiment 3

[0043]The hepatitis A vaccine containing oligochitosan adjuvant provided in this example is: add 10 mg of chitosan oligosaccharide to each vaccine dose, add chitosan oligosaccharide dissolved in 120 μL sterile water to hepatitis A (HAV) antigen, and then add Physiological saline to 200 μL, and mix uniformly according to the routine to obtain the hepatitis A vaccine agent containing chitosan oligosaccharide. Wherein, chitosan oligosaccharide, HAV antigen are with embodiment 1;

[0044] The immunization experiment of the hepatitis A vaccine that this example gained contains the chitosan oligosaccharide adjuvant is the same as embodiment 1, and the results are shown in Table 3.

[0045] Table 3 is after using the adjuvant that embodiment 2 provides, within 16 weeks, each experimental group mouse serum anti-HAV IgG antibody level:

[0046] table 3

[0047]

[0048] It can be seen from the data analysis that from the 4th week after immunization, all experimental groups except ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides anapplication of chitosan oligosaccharide and a vaccine containing the chitosan oligosaccharide. The chitosan oligosaccharide is applied to the vaccine as an adjuvant, namely each single vaccine contains 2.5-10mg of chitosan oligosaccharide. The chitosan oligosaccharide provided by the invention is a chitosan oligosaccharidemixturewhich is formed by 2-10 glucosamines and of which the molecular weight is smaller than 3000, and is small in toxic or side effect, and is safe and reliable when being used in an immunizing dose range; antigen-specifichumoral immune responsecan be effectively induced; the induced humoral immune response effect is superior to that of a group free of an adjuvant; and the chitosan oligosaccharide is available in raw materialwhich is a commercially available product, is simple in preparation technology, low in cost, stable in performance, relatively high in biological potency, and free of a toxic or side effect, and can be add to a plurality of traditional vaccines or genetic engineering vaccines as the adjuvant.

Description

technical field [0001] The invention relates to an application of chitosan oligosaccharide and a vaccine agent containing chitosan oligosaccharide, belonging to the technical field of immunology. Background technique [0002] With the continuous deepening of vaccine research, especially the rapid development of molecular biology technology, new genetic engineering vaccines have high purity and strong specificity, but small molecules and relatively poor immunogenicity make it difficult to produce effective immune responses. agent to enhance its immunogenicity. The currently internationally approved adjuvants that can be used in humans include aluminum salts, MF59, AS03 and AS04. Aluminum salt adjuvants have long been proven in practice to improve antibody levels and safety, but due to their shortcomings such as causing allergies and inducing degenerative neuropathy, there is an urgent need to develop new vaccine adjuvants to overcome these defects and better serve human bein...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/39A61P37/04A61P31/14A61P31/20A61K39/205A61K39/29
Inventor 李萍王海漩乌美妮李彦涵孙静李建芳胡凝珠胡云章施建东
Owner INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap